Tecovirimat

Summary

Tecovirimat (CHEMBL1257073) is an approved small molecule (ATC J05AX24); indicated across 2 conditions including viral infectious disease and smallpox.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AX24
• Indications: 2 conditions
• Clinical trials: 14
• Chemistry: 376.3 Da · C19H15F3N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1257073
Name	Tecovirimat
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	16124688
ATC	J05AX24
Molecular formula	C19H15F3N2O3
Molecular weight	376.3
InChIKey	CSKDFZIMJXRJGH-VWLPUNTISA-N

SMILES: C1[C@@H]2[C@H]1[C@@H]3C=C[C@H]2[C@@H]4[C@H]3C(=O)N(C4=O)NC(=O)C5=CC=C(C=C5)C(F)(F)F

IUPAC name: N-[(1R,2R,6S,7S,8S,10R)-3,5-dioxo-4-azatetracyclo[5.3.2.02,6.08,10]dodec-11-en-4-yl]-4-(trifluoromethyl)benzamide

Also known as: SIGA-246, ST 246, ST-246, Tecovirimat, Tpoxx, TECOVIRIMAT, C0088730

Parent form; salt/anhydrous children: CHEMBL5315121

Patent coverage: 140 distinct patent families (307 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Envelope phospholipase OPG057.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P04021	8.57	IC50	2.66	nM	CHEMBL_ACT_23286378

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
smallpox	4	MONDO:0004651	MONDO:0004651

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE3	5
PHASE4	3
PHASE2	3
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06156566	PHASE4	RECRUITING	European Trial Into Mpox Infection
NCT04392739	PHASE4	COMPLETED	Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
NCT04485039	PHASE4	COMPLETED	Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
NCT05597735	PHASE3	ACTIVE_NOT_RECRUITING	Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
NCT02474589	PHASE3	COMPLETED	A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
NCT04971109	PHASE3	COMPLETED	Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
NCT05534165	PHASE3	SUSPENDED	Tecovirimat in Non-hospitalized Patients With Monkeypox
NCT05534984	PHASE3	TERMINATED	Study of Tecovirimat for Human Mpox Virus
NCT04957485	PHASE2	ACTIVE_NOT_RECRUITING	Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
NCT00907803	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
NCT05559099	PHASE2	COMPLETED	Tecovirimat for Treatment of Monkeypox Virus
NCT00303225	PHASE1	WITHDRAWN	SIGA-246 to Treat Smallpox
NCT00431951	PHASE1	COMPLETED	Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
NCT02080767	Not specified	AVAILABLE	Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).